Alaunos Therapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing the pricing and closing of a registered direct offering that generated approximately $915,400.50 in net proceeds.
Key Highlights
- Shares offered: 380,469 shares of common stock at $1.46 per share, plus 386,654 pre-funded warrants at $1.459 per warrant.
- Net proceeds: Approximately $915,400.50, after deducting estimated offering expenses and placement agent fees.
- Closing date: The offering closed on September 21, 2026.
- Placement agent: Dawson James Securities, Inc. acted as exclusive placement agent and received a cash fee of 8% of aggregate gross proceeds.
- Use of proceeds: The company disclosed it intends to use net proceeds for general corporate purposes, including working capital.
- Lock-up period: Officers and directors agreed not to offer, sell, or transfer shares of company capital stock for 15 days from the date of the offering.
Alaunos Therapeutics Registered Direct Offering: Terms and Structure
According to the filing, Alaunos Therapeutics, Inc. (NASDAQ:TCRT) entered into a securities purchase agreement on September 18, 2026, with accredited investors named on the signature pages. Under the agreement, the company agreed to sell 380,469 shares of common stock, par value $0.001 per share, at $1.46 per share, and 386,654 pre-funded warrants at a purchase price of $1.459 per warrant. The offering was made pursuant to a Registration Statement on Form S-3, as amended (File No. 333-289748), which was filed on November 7, 2025, and became effective on November 27, 2025.
The filing explains that pre-funded warrants were offered to purchasers whose acquisition of common stock would have resulted in beneficial ownership exceeding 4.99% of the outstanding common stock immediately following the offering. The pre-funded warrants carry an exercise price of $0.001 per share, have no expiration date, and are subject to a 4.99% beneficial ownership limitation, which may be raised to 9.99% upon 60 days advance notice to the company. The 60-day period cannot be waived, according to the filing.
Dawson James Securities, Inc. served as exclusive placement agent. The company paid the placement agent a cash fee equal to 8% of aggregate gross proceeds and reimbursed certain of the placement agent's expenses, the filing disclosed. Each of the company's officers and directors also entered into lock-up agreements restricting transfers or disposals of company capital stock for 15 days from the date of the offering, subject to certain exceptions.
What Was Disclosed
Alaunos Therapeutics disclosed the entry into a securities purchase agreement, the closing of a registered direct offering generating approximately $915,400.50 in net proceeds, placement agent compensation terms, pre-funded warrant terms, and officer and director lock-up commitments.



Please wait processing your request...